Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENT
2015-005242-60Phase 4Unknown
- Sponsor
- University of Liverpool
- Start
- Jul 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Exenatide once weekly + dapagliflozin with Dapagliflozin + placebo (2 arms). Status: unknown.
02
Drugs
dapagliflozinexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-005242-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005242-60.